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Background: Structural maintenance of chromosomes 1A (SMC1A) is a member of the cohesion family of proteins
that plays crucial roles in cell cycle control. Recent studies have concluded that SMC1A is involved in the
pathogenesis of cancer. This study aims to evaluate the functional role of SMC1A in colorectal cancer (CRC) both
in vitro and in vivo, and the underlying molecular mechanisms.
Methods: We firstly investigated the expression levels of SMC1A in 427 CRC specimens. Antigen expression was
determined by immunohistochemical analysis of SMC1A on tissue microarrays. Stable SMC1A knockdown CRC cell
lines were employed. The effects of SMC1A depletion on cell growth in vitro were examined by MTT, colony
formation and flow cytometry assays. Tumor forming was evaluated by nude mice model in vivo. To detect the
activation of intracellular signaling, pathscan intracellular signaling array and western blotting were performed.
Results: The expression of SMC1A was much stronger in CRC tumor tissues than in adenomas and normal
colorectal tissues. High SMC1A expression, indicated as an independent poor prognostic predictor for patients with
stage III and stage IV CRC, was correlated with overall survival (OS) (p = 0.008). Functional analysis indicated that
SMC1A knockdown by small interfering RNA (siRNA) mediated the significant inhibition of cell proliferation; induced
cell cycle arrest and apoptosis via the suppression of CDK4, PCNA and PARP; and blocked the activation of the
Erk1/2 and Akt cascades in CRC cells. In addition, SMC1A depletion significantly decreased the growth of
subcutaneously inoculated tumors in nude mice.
Conclusions: These results suggest that SMC1A plays an essential role in the development of CRC and may be a
predictive factor in patients with CRC. The inhibition of SMC1A may serve as a promising therapeutic strategy for
human CRC.
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Colorectal cancer (CRC) is the second leading cause of
malignancy-related death after lung cancer [1]. If diag-
nosed at the early stages, CRC can be cured with surgery
[2]. However, in most instances, the cancer has progressed
to the malignant stage at the time of diagnosis [3]. More-
over, the mortality is increasing due to cancer metastasis
[4,5]. Therefore, novel therapeutic strategies for the treat-
ment of CRC are being widely researched. The identifica-
tion of biomarkers related to CRC development and
progression is a novel aspect of cancer research. Several
genetic and epigenetic factors have been found to be* Correspondence: laoxydr@163.com
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unless otherwise stated.involved in the progression of CRC [6]. These factors alter
the apoptosis process of the cancer cells and facilitate cell
growth and survival over normal cells [7]. In this regard,
studies using RNA interference (RNAi) technology to
target oncogenes have become popular [8].
Cohesin is a multiunit complex containing four subunits:
a pair of SMC (structural maintenance of chromosomes)
proteins, SMC1A and SMC3, and two non-SMC proteins,
RAD21/Scc1 and STAG/Scc3/Sa. It associates with chro-
matin after mitosis and is important for holding sister
chromatids together following DNA replication [9]. More-
over, the cohesion complex is required to regulate DNA
damage-induced intra-S phase and G2/M checkpoints in
mammalian cells because it facilitates the recruitment of
proteins involved in cell cycle checkpoints [10]. The SMCThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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SMC6) with different functions and distinct biochemical
activities [11]. SMC1 serves as a target for the ATM pro-
tein, which is responsible for controlling DNA replication
and repair in human cells [12]. SMC1A is a conserved
member of the cohesion complex from yeast to humans,
which has important roles in maintaining genome stability
[13]. Mutation and deregulation of SMC1A are highly rele-
vant to diverse human diseases, including Cornelia de
Lange syndrome and malignant carcinomas. Narayan et al.
demonstrated an upregulation of SMC1A mRNA in cervix
cancer cells compared to normal cervix [14]. Recently,
SMC1A was found to be associated with cell growth and
survival in lung adenocarcinoma [15] and glioblastoma
[16,17]. However, little is known concerning the possible
role of SMC1A in human CRC.
Mutations of SMC1 have been identified in colorectal
cancers [18]. Therefore, this study was designed to identify
the relationship between SMC1A expression and CRC
development. Additionally, the potential use of RNAi-
mediated SMC1A gene knockdown as a therapeutic target
against colon cancer progression was analyzed using
in vitro and in vivo colon cancer cell models.Methods
Patients and cell lines
The study population comprised three groups. Group A
included 56 patients with normal rectal mucosa. Samples
were obtained from patients with severe mixed hemor-
rhoids who underwent the Procedure for Prolapse and
Hemorrhoids. All patients had morphologically normal
colorectal mucosa that was free of neoplastic or inflam-
matory disease as confirmed by preoperative colonos-
copy. Group B included 51 patients with colorectal
adenomatous polyps. All these polyps were resected
endoscopically and proven to be adenomas by postoper-
ative pathological examination. Group C included 427
patients with sporadic CRC, including 53 patients with
stage I disease, 159 with stage II disease, 160 with stage
III disease and 55 with stage IV disease. Each patient
had an available specimen of a resected primary CRC.
All patients with CRC were classified according to the
TNM staging system using the International Union
Against Cancer criteria. Patients who were diagnosed
with cancers of any other histotype and those with a
family history of CRC were excluded from the study. We
enrolled 427 CRC patients with a median age of 60 years
(range, 20–87 years), and 240 of these patients were
male. All 427 patients did not receive preoperative
chemotherapy or radiotherapy. However, patients with
stage III and stage IV disease received 5-fluorouracil-
based systemic chemotherapy after surgery. Postopera-
tive adjuvant radiation was also administered to thosepatients with stage III and stage IV CRC. Patients were
followed until death or December 18, 2011, with a mean
postoperative follow-up duration of 40 months. Disease-
free survival (DFS) was defined as the duration from the
date of surgery to the date of first confirmed disease
recurrence or to the date of the last follow-up for those
without disease recurrence. All patients underwent
surgery in the Department of Colorectal Surgery, The
Second Affiliated Hospital, Medical School of Zhejiang
University, China between April 2001 and December
2009. All patients provided informed consent. This study
was approved by the Committee on Ethics of Biomedical
Research, The Second Affiliated Hospital, Medical
School of Zhejiang University, China.
Human CRC cell lines were obtained from Chinese
Academy of Sciences Cell Bank of Type Culture Col-
lection (SW480: #TCHu172, SW620: #TCHu101, RKO:
#TCHu116, DLD-1: #TCHu134, HCT 116: #TCHu 99)
and maintained in RPMI1640 (Hyclone) supplemented
with 10% heat-inactivated FBS at 37°C in a humidified
atmosphere of 5% CO2. Human embryonic kidney cell
line (HEK-293: #GNHu43) was maintained in DMEM
(Hyclone) supplemented with 10% heat-inactivated
FBS and penicillin/streptomycin.Tissue microarray and immunohistochemistry (IHC)
All CRC cases were histologically reviewed by
hematoxylin and eosin staining, and representative areas
were premarked in paraffin blocks, away from necrotic
and hemorrhagic materials. Cylinders measuring 1.5 mm
in diameter were then taken from the paraffin blocks.
Finally, 4 different tissue microarray (TMA) blocks were
constructed, containing a total of 534 cores (56 normal
mucosa cores, 51 adenoma cores and 427 CRC cores).
Sections of 4-μm thickness were placed on three
aminopropyltriethoxysilane-coated slides.
Immunohistochemistry (IHC) was performed using a
standard streptavidin-biotin-peroxidase complex method
as described in our previous report [19]. Slides were
incubated overnight at 4°C with anti-SMC1A (1:200,
Santa Cruz Biotechnology, Inc) and the antibody specifi-
city was validated according to a previous report [20].
SMC1A expression was estimated based on the percent-
age and intensity of the stained tumor cells. The staining
percentage was graded as 0 (0-5%), 1 (6-20%), 2 (21-
60%) and 3 (61-100%), and the staining intensity was
graded as 0 (negative), 1 (weak), 2 (moderate) and 3
(strong). The sum of the intensity and extent score was
used as the final staining score (0–6). Tumors with final
staining scores of 0, 1, 2–4 and 5–6 were considered to
be negative (−), slightly positive (+), moderately positive
(++) and strongly positive (+++), respectively, as de-
scribed previously [21,22].
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infection into cancer cells
The short hairpin RNA (shRNA) for human SMC1A
(GenBank: NM_006306) (5′-CTAGCCCGGGCCGGGA
CTGTATTCAGTATACTCGAGTATACTGAATACAGT
CCCGGCTTTTTTGTTAAT-3′) was screened and vali-
dated to be a candidate shRNA. A non-silencing siRNA
(5′-TTCTCCGAACGTGTCACGT-3′) was used as con-
trol. To eliminate the possible off-target effects of shRNA,
another shRNA against SMC1A (5′- TAACAAAAAAGC
CGGGACTGTATTCAGTATACTCGAGTATACTGAAT
ACAGTCCCGGCCCGGG-3′) was used to obtain com-
parable results. The oligos were inserted into the pFH-L
vector (Holly Lab Shanghai). The lentiviral particles were
constructed according to previous report [23]. RKO and
SW480 cells were infected with lentivirus containing
SMC1A shRNA (Lv-shSMC1A) or control shRNA
(Lv-shCon) at an MOI of 30 or 60, respectively. The cells
(50,000 cells/well) were seeded in 6-well plates, and suc-
cessful infection was confirmed after 72 h by observation
through a fluorescence microscope for green fluorescence
protein expression.
Real-time quantitative PCR analysis
RT-PCR analysis was performed using the SYBR Green
Master Mix Kit in the DNA Engine Opticon™ System (MJ
Research, Waltham, MA) as described in previous reports
[24]. Beta-actin was used as an internal control. The
primers of SMC1A were 5′-GCAGCAGCAGCAGATTGA
G-3′ (forward) and 5′-TCTCTTCTTCCATCCGTTCTTC-
3′ (reverse). The primers of β-actin were 5′-GTGGACATC
CGCAAAGAC-3′ (forward) and 5′-AAAGGGTGTAACG
CAACTA-3′ (reverse). The relative gene expression levels
were calculated and statistically compared using the 2-ΔΔCT
analysis program.
MTT assay
After lentivirus infection, RKO and SW480 cells were
seeded at 1.2 × 103 cells/well and 2 × 103 cells/well,
respectively, into 96-well plates. Cell viability was analyzed
using the MTT assay. Briefly, 20 μl of the MTT solution
(5 mg/ml) was added to each well after 1–5 days. The
samples were incubated at 37°C for 4 h, and then dissolved
in 100 μl of acidic isopropanol (10% SDS, 5% isopropanol
and 0.01 mol/L HCl). The optical density was measured
using a microplate reader at 595 nm.
Colony formation assay
Lentivirus-transduced cells (200 cells/well) were seeded
into 6-well plates and the medium was replaced every
three days. After 8 days of incubation, cells were washed
with PBS and fixed with 4% paraformaldehyde for
30 min at room temperature. The fixed cells were
stained with Giemsa (Merck) for 20 min, washed withwater and air-dried. The total number of colonies with
more than 50 cells was counted using a light microscope
and a fluorescence microscope.
Flow cytometry analysis
After lentivirus infection, RKO cells (1 × 105 cells/dish)
were seeded on 6-cm dishes and collected until 80% con-
fluence. The cells were then fixed by suspension in 0.7 ml
of 70% ethanol for 30 min at 4°C. The ethanol was dis-
carded after centrifugation, and a propidium iodide (PI,
100 μg/ml) solution containing 10 μg/ml of DNase-free
RNase A was added to stain the cells, followed by incuba-
tion for 30 min at room temperature. The cell suspension
was next filtered through a 50-μm nylon mesh, and 10,000
stained cells were analyzed using flow cytometer (Cell Lab
Quanta, Beckman Coulter).
Apoptosis was detected by Annexin V-APC/7-AAD
apoptosis detection kit (KeyGEN Biotech, Nanjing,
China) following manufacturer’s instructions.
Tumorigenesis in nude mice
Five- to six-week-old nude mice were inoculated with
RKO cells. Prior to inoculation, three groups of RKO
cells were prepared: Lv-shSMC1A-infected RKO cells,
Lv-shCon-infected RKO cells and non-infected RKO
cells. Twenty-four mice were randomized into three
groups with eight mice in each group. Next, after the
passage of three generations, the cells were suspended in
physiological saline solution at a cell density of 5 × 107
cells/ml. From the cell suspension, 0.2 ml was injected
subcutaneously into the mice using a 6-gauge, 1-ml nee-
dle. The mice were reared until the tumor was visible to
the naked eye. The measurements of the tumor (diam-
eter and size) were measured at 6, 9, 12, 15 and 20 days
after inoculation. The mice were euthanized after 20 days
of inoculation, and then the size and weight of the colon
tumors were measured and compared among the three
groups. All animal treatments were performed strictly in
accordance with international ethical guidelines and the
National Institutes of Health Guide concerning the Care
and Use of Laboratory Animals. The experiments were
approved by the Institutional Animal Care and Use
Committee of Zhejiang University.
Path Scan intracellular signaling array and Western blot
analysis
To detect the activation of intracellular signaling, the
PathScan intracellular signaling array was used. Briefly,
5 days after lentivirus infection, RKO cells were collected
and lysed. Intracellular signaling was detected using a
PathScan intracellular signaling array kit (Cell Signaling
Technology) following the manufacturer’s instructions.
Western blot was performed according to standard
protocols, as described previously [25]. The primary
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(1:200, Santa Cruz Biotechnology, Inc); anti-GAPDH
(1:3000, Santa Cruz Biotechnology, Inc); anti-Erk (1:2000,
Santa Cruz Biotechnology, Inc); anti-phospho-Erk1/2
(1:2000, Signalway Antibody); anti-PCNA (1:1500, MBL);
anti-PARP and anti-CDK4 (1:1000, all from Cell Signaling
Technology).
Statistical analysis
Associations between SMC1A expression and clinico-
pathological variables were analyzed by Pearson Chi-
Square test. The median OS and DFS, as well as their
95% confidence intervals (95% CIs), were estimated by
the Kaplan-Meier method. The difference in survival
was analyzed using the log-rank test. Student’s t-test was
used to evaluate the differences between the SMC1A si-
lenced and non-silenced groups. A p value less than 0.05
(two-sided) was considered to be statistically significant.
All statistical analyses were conducted using SPSS17.0
statistical software (SPSS Inc, Chicago, IL).
Results
SMC1A expression in normal mucosa, adenoma and stage
I to IV CRC
The expression of SMC1A in normal mucosa, adenoma
and stage I to IV CRC is presented in Table 1. Strong
SMC1A expression in CRC tissues was significantly higher
than that in matched adenoma and normal mucosa. There
were significant differences noted regarding SMC1A ex-
pression among these three groups (p = 0.015). Represen-
tative photomicrographs of four degrees of SMC1A
expression intensity are shown in Figure 1A-D.
Correlation between SMC1A expression and
clinicopathologic parameters of patients with CRC
The association between SMC1A expression and the
clinicopathologic parameters is shown in Table 2. Higher
expression of SMC1A was found to be significantly asso-
ciated with distant metastasis (p = 0.022) and higher
TNM stage of disease (p < 0.001). In addition, SMC1A
expression in colon cancer was much higher than that
in rectal cancer (p < 0.001). No significant association
was observed between SMC1A expression and patient
gender, patient age, invasion depth, tumor differentiation,
serum CEA level, serum CA19-9 level or recurrence.Table 1 Expression of SMC1A in normal mucosa, adenoma an
Characteristic Total SMC1A immunosta
-
Normal mucosa 53 6 (11.3%)
Adenoma 50 10 (20.0%)
Colorectal cancer (Stage I-IV) 426 41 (9.6%)
ausing Pearson Chi-Square test. 5 cases are missing (0.9%).Correlation between SMC1A expression and survival in
patients with CRC
In late stage (stage III and stage IV) CRC cases, a higher
SMC1A expression was found to be significantly associ-
ated with worse OS (p = 0.008) (Figure 1E). The OS of
those patients with negative SMC1A expression (−) was
significantly higher than that of patients with strong
positive SMC1A expression (+++). The DFS of patients
with negative SMC1A expression (−) was also obviously
higher than that of patients with strong positive SMC1A
expression (+++) (Figure 1F).
shRNA-mediated SMC1A knockdown efficiency in CRC
cells
As shown in Figure 2A, the expression of SMC1A was ob-
served in all five CRC cell lines. RKO and SW480 cell lines
were used to investigate loss of function in the following
study. Both cell lines were cultured and successfully in-
fected with Lv-shCon or Lv-shSMC1A with an infection
rate greater than 80%. The expression levels of SMC1A
were significantly decreased (p < 0.01) in Lv-shSMC1A
groups (Figure 2B and C). Similar result was observed in
RKO cells treated with another shRNA against SMC1A.
These results indicated that the lentivirus-mediated
shRNA targeting SMC1A could effectively knock down
SMC1A expression in CRC cells.
Functional analysis of SMC1A by shRNA in CRC cells
As shown in Figure 2D and F, the proliferation rates of
Lv-shSMC1A-infected cells started to decrease and were
significantly reduced compared with Lv-shCon groups at
the 4th and 5th days. Moreover, the number and size of
the colonies were remarkably decreased in both RKO
and SW480 cells after SMC1A knockdown (Figure 2G
and I). Similar results were observed in RKO cells
treated with another shRNA against SMC1A (Figure 2E
and H). These results indicated that SMC1A could play
an essential role in CRC cell proliferation and tumori-
genesis in vitro.
To examine the mechanism underlying the inhibition
of cell growth, the cell cycle distribution and apoptosis
were detected in RKO cells after lentivirus infection. As
shown in Figure 2J, compared with Lv-shCon groups,
the percentages of cells in the G0/G1 and G2/M phases
were significantly increased, whereas the number of cellsd stage I to IV colorectal cancer (n = 534)
ining Pa
+ ++ +++
32 (60.4%) 14 (26.4%) 1 (1.9%) 0.015
31 (62.0%) 9 (18.0%) 0 (0.0%)
207 (48.6%) 162 (38.0%) 16 (3.8%)
Figure 1 SMC1A staining is demonstrated mainly at the membrane of tumor cells. Positive cells were stained brown. The intensity of
SMC1A staining was assigned the following scores: negative = − (A), slightly positive = + (B), moderately positive = ++ (C) and strongly
positive = +++ (D). Examples of representative immunohistochemistry results are shown. Scale bars = 50 μm. Kaplan-Meier analysis of (E)
overall survival (p = 0.008) and (F) disease-free survival (p = 0.087) for SMC1A expression in patients with high-grade (stage III and stage IV)
CRC (n = 215) is shown.
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infected with Lv-shSMC1A. Moreover, in the absence of
SMC1A, more cells were obviously accumulated in the
sub-G1 phase representing apoptotic cells. As shown in
Figure 2K, Annexin V-APC vs 7-AAD plots from the
gated cells showed the populations corresponding to
viable and non-apoptotic (Annexin V−/7-AAD−), early
(Annexin V+/7-AAD−), and late (Annexin V+/7-AAD+)
apoptotic cells. After Lv-shSMC1A infection, more cells
were Annexin V positive and 7-AAD negative, which
represents early apoptosis. These results indicated that
the cell cycle was arrested in the G0/G1 and G2/M
phases and that RKO cells were entering early apoptotic
stage after SMC1A knockdown.
Effect of SMC1A knockdown on tumorigenesis in vivo
The effects of SMC1A silencing on the development of
colon tumors were analyzed in vivo using nude mouse
models. As shown in Figure 3A and B, the size of the tu-
mors was significantly decreased after SMC1A knockdown
in a time course of 20 days. Moreover, the time-dependent
analysis showed that the development of tumors peaked
after 15 days, and the volume of the tumors was sig-
nificantly suppressed in mice inoculated with SMC1A-
silenced RKO cells compared with control groups
(Figure 3C). Furthermore, the weight of the tumors
was also remarkably decreased (p < 0.001) in SMC1A-
silenced mice (Figure 3D). These results were confirmedby analysis of the protein content of SMC1A in tissues of a
subcutaneous xenograft murine model. The SMC1A ex-
pression level was completely suppressed in tumor tissues
by the infection with SMC1A shRNA (Figure 3E). This
finding indicated that colon tumorigenesis was significantly
inhibited by the absence of SMC1A.
Mechanism study of SMC1A silencing in CRC cells
To investigate the regulatory mechanism of SMC1A in
the tumorigenesis of CRC, multiple signaling pathways
were analyzed in SW480 cells after SMC1A knockdown.
SMC1A-triggered signal transduction was determined
using the PathScan intracellular signaling array kit. Knock-
down of SMC1A obviously inhibited the activation of Akt
and induced the activation of PRAS40 (Figure 4A). More-
over, depletion of SMC1A significantly inhibited the phos-
phorylation of Erk1/2, indicating that SMC1A affected cell
proliferation possibly via the tyrosine kinase-activated
Ras/MEK/Erk pathway and Ras/PI3K/Akt pathway. In
addition, SMC1A silencing decreased the expression levels
of CDK4, PCNA and PARP in SW480 cells, indicating that
CDK4, PCNA and PARP play important roles in SMC1A-
induced cell cycle arrest and apoptosis (Figure 4B). Fur-
thermore, a signaling pathway resource with multi-layered
regulatory networks was applied to identify SMC1A-
related signaling molecules (Figure 4C). Further studies
are needed to clarify the mechanisms of SMC1A in CRC
progression.
Table 2 Relationship of SMC1A expression and clinicopathological parameters in colorectal cancer patients (n = 427)
Characteristic N SMC1A immunostaining Pa
- + ++ +++
Gender (n) 0.067
Male 240 21 (8.8%) 128 (53.3%) 80 (33.3%) 11 (4.6%)
Female 186 20 (10.8%) 79 (42.5%) 82 (44.1%) 5 (2.7%)
Age (years) 0.193
≤60 227 27 (11.9%) 112 (49.3%) 82 (36.1%) 6 (2.6%)
>60 199 14 (7.0%) 95 (47.7%) 80 (40.2%) 10 (5.0%)
Position <0.0001
Colon cancer 209 6 (2.9%) 99 (47.4%) 93 (44.5%) 11 (5.3%)
Rectal cancer 217 35 (16.1%) 108 (49.8%) 69 (31.8%) 5 (2.3%)
Invasion depth 0.388
T1-T2 79 11 (13.9%) 34 (43.0%) 32 (40.5%) 2 (2.5%)
T3-T4 347 30 (8.6%) 173 (49.9%) 130 (37.5%) 14 (4.0%)
Lymph node metastasis 0.001
N0 229 10 (4.4%) 107 (46.7%) 103 (45.0%) 9 (3.9%)
N1 131 19 (14.5%) 65 (49.6%) 41 (31.3%) 6 (4.6%)
N2 66 12 (18.2%) 35 (53.0%) 18 (27.3%) 1 (1.5%)
Distant metastasis 0.022
M0 372 40 (10.8%) 186 (50.0%) 133 (35.8%) 13 (3.5%)
M1 54 1 (1.9%) 21 (38.9%) 29 (53.7%) 3 (5.6%)
TNM <0.0001
I 53 7 (13.2%) 22 (41.5%) 23 (43.4%) 1 (1.9%)
II 159 3 (1.9%) 77 (48.4%) 71 (44.7%) 8 (5.0%)
III 160 30 (18.8%) 87 (54.4%) 39 (24.4%) 4 (2.5%)
IV 54 1 (1.9%) 21 (38.9%) 29 (53.7%) 3 (5.6%)
Tumor differentiation 0.161
Well 13 1 (7.7%) 7 (53.8%) 5 (38.5%) 0 (0.0%)
Moderately 358 30 (8.4%) 170 (47.5%) 143 (39.9%) 15 (4.2%)
Poorly 55 10 (18.2) 30 (54.5%) 14 (25.5%) 1 (1.8%)
Serum CEA 0.190
≤5 ng/mL 280 21 (7.5%) 137 (48.9%) 112 (40.0%) 10 (3.6%)
>5 ng/mL 146 20 (13.7%) 70 (47.9%) 50 (34.2%) 6 (4.1%)
Serum CA199 0.776
≤37 U/ml 358 31 (8.7%) 176 (49.2%) 138 (38.5%) 13 (3.6%)
>37 U/ml 65 8 (12.3%) 31 (47.7%) 23 (35.4%) 3 (4.6%)
Recurrence 0.536
No 338 34 (10.1%) 161 (47.6%) 132 (39.1%) 11 (3.3%)
Yes 88 7 (8.0%) 46 (52.3%) 30 (34.1%) 5 (5.7%)
ausing Pearson Chi-Square test. 1 case is missing (0.2%).
Wang et al. BMC Cancer  (2015) 15:90 Page 6 of 11Discussion
SMC1A is a member of the cohesion complex that is in-
volved in critical cellular functions such as DNA repair,
cell cycle progression, gene expression regulation and
the maintenance of genome stability [11,26]. Addition-
ally, dysfunction of the proteins in the cohesion complexwas found to lead to genome instability, which is directly
related to cancer development. In the present study, we
found that SMC1A expression was significantly elevated
in human CRC tissues. In addition, the increased expres-
sion of SMC1A was positively associated with worse
clinicopathologic variables, including distant metastasis
Figure 2 (See legend on next page.)
Wang et al. BMC Cancer  (2015) 15:90 Page 7 of 11
(See figure on previous page.)
Figure 2 Functional analysis of SMC1A by shRNA in CRC cells. (A) Expression analysis of SMC1A in five different CRC cell lines by real-time
PCR (upper panel) and western blotting (lower panel). (B) Expression analysis of SMC1A in RKO cells after Lv-shSMC1A infection by real-time PCR
(upper panel) and western blotting (lower panel). (C) Expression analysis of SMC1A in SW480 cells after Lv-shSMC1A infection by real-time PCR
(upper panel) and western blotting (lower panel). β-actin gene and GAPDH protein were used as internal controls. The proliferation levels of RKO
(D, E) and SW480 (F) cells after Lv-shSMC1A infection analyzed by the MTT assay. The number of colonies in RKO (G, H) and SW480 (I) cells after
Lv-shSMC1A infection analyzed by the colony formation assay. (J) The percentages of RKO cells using three different treatments in different
phases (left panel) and the sub-G1 phase (right panel) of the cell cycle. (K) RKO cells stained with Annexin V and 7-AAD analyzed using flow cytometer
(left panel). Q1, Annexin V−/7-AAD+; Q2, Annexin V+/7-AAD+; Q3, Annexin V−/7-AAD−; Q4, Annexin V+/7-AAD−. Quantification of the percentage of early
apoptotic cells and late apoptotic cells (right panel). *p < 0.05, **p < 0.01, ***p < 0.001 in comparison with non-silencing shRNA infected control.
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current study demonstrated a significant correlation
between SMC1A overexpression and shortened OS in
patients with advanced CRC. Metastasis and a higher
TNM stage are widely believed to be responsible for the
worse prognosis noted among patients with CRC. These
results suggest that patients with CRC with a higher
expression of SMC1A in their tumors have a worse OS.
Previous studies have reported that RNAi-mediated
gene silencing could be effectively used to suppress the
proliferation of colon cancer cells in vitro [7,27]. In the
present study, the CRC cell models and mouse models
were shown to express elevated amounts of SMC1A.
These findings suggested that the overexpression of
SMC1A resulted in genome instability and led to the
development and progression of CRC cells. shRNA-
mediated SMC1A knockdown resulted in a significantFigure 3 Effect of SMC1A silencing on the tumorigenesis of CRC in vi
images of tumors formed in the mice in which Lv-shSMC1A- or Lv-shCon-i
on the 6th, 9th, 12th, 15th and 21st days after the cells were implanted sub
silencing. (E) Expression analysis of SMC1A in tumor tissues collected from midown-regulation of cell proliferation, colony formation,
cell cycle progression and a significant up-regulation of
apoptosis in CRC cells. Our results were coincident with
the outcome of SMC1A silencing in lung adenocarcin-
oma cells, in which cell growth was suppressed through
G0/G1 phase cell cycle arrest and apoptosis [15]. Also,
knocking down SMC1A inhibited growth and led to G2/
M arrest in glioma cells [17]. From these data, we sug-
gest that SMC1A plays an essential role in CRC cell
growth. Moreover, the size of colon tumors was signifi-
cantly decreased in the absence of the SMC1A gene,
indicating that the up-regulated expression of SMC1A has
a positive impact on the progression of CRC cells and that
shRNA-mediated gene silencing effectively down-regulates
CRC progression in both in vitro and in vivo models.
Intracellular signaling array showed that SMC1A deple-
tion inhibited the activation of Akt and induced thevo. (A) The subcutaneous xenograft murine model. (B) Representative
nfected RKO cells were implanted. (C) Changes in the tumor volume
cutaneously. (D) Changes in the tumor weight in mice after SMC1A
ce. ***p < 0.01 in comparison with non-silencing shRNA infected control.
Figure 4 Mechanism study of SMC1A silencing in CRC cells. (A) Intracellular signaling array after Lv-shSMC1A infection. (B) Western blotting
analysis of SMC1A-related signaling molecules in RKO cells. (C) SignaLink 2.0 analysis of SMC1A-related signaling molecules in RKO cells.
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and Thr308 by the TORC2 complex and PDK1, respect-
ively, are reliable predictors of Akt activation. Phosphoryl-
ation of PRAS40 at Thr246 by Akt relieves the PRAS40
inhibition of TORC1 [28]. PRAS40 knockdown reduced
the ability of tumor necrosis factor (TNF)-α and cyclohex-
imide to induce apoptosis in HeLa cells [29]. Further ana-
lysis demonstrated that SMC1A silencing attenuates the
activation of Erk1/2 and Akt, which are generally activated
in response to growth factor stimulation that transmits
growth and survival signals [30]. Thus, the mechanisms of
SMC1A knockdown restricting CRC cell growth may
occur, in part, via the blockade of Akt and MAP kinase
activation. Cyclins and cdks are two types of crucial regu-
latory molecules that determine cell cycle progression
[31]. Cyclin D1 binding to CDK4/6 forms the active com-
plex of Cyclin D1-CDK4/6, which phosphorylates retino-
blastoma protein (pRb) and subsequently releases E2F
transcription factors, resulting in the activation of specific
gene expression required for G1 to S phase progression[19]. Moreover, SMC1A was suggested to regulate CDK4
as analyzed by SignaLink 2 [32,33]. Cell cycle analysis
showed that SMC1A knockdown restricted G1 to S phase
progression, and further investigation demonstrated that
SMC1A silencing down-regulated the expression of
CDK4. PCNA is a member of the DNA sliding clamp fam-
ily of proteins that assists in DNA replication and repair,
and considered to be a marker of cell proliferation in
various cancers [34]. In addition, PCNA also forms
complexes with Cyclin-CDK complexes and acts as a
connector between CDK and its substrates, stimulating
their phosphorylation and thus controlling cell cycle
progression [35,36]. Poly-ADP-ribose polymerase
(PARP), a member of the PARP enzyme family, is an
abundant DNA-binding enzyme that detects and sig-
nals DNA strand breaks [37]. The presence of cleaved
PARP-1 is one of the most used diagnostic tools for the
detection of apoptosis in many cell types [38]. Our
results revealed that SMC1A silencing also down-
regulates PCNA and PARP expression. Collectively, the
Wang et al. BMC Cancer  (2015) 15:90 Page 10 of 11mechanisms of SMC1A knockdown inhibiting CRC cell
proliferation and cell cycle progression may occur, in
part, via the blockade of Akt and MAP kinase activation
and the subsequent suppression of CDK4 and PCNA.
Knockdown of SMC1A induced apoptosis, potentially due
to the induction of PRAS40 and the cleavage of PARP.
Conclusions
SMC1A may be a predictive factor in patients with CRC,
in whom high SMC1A expression is predictive of a poor
prognosis. In the absence of SMC1A, cell proliferation,
cell cycle progression and tumor development were effect-
ively suppressed. Therefore, shRNA-mediated SM1CA
silencing could be an effective therapeutic tool for colon
cancer treatment. We propose that the overexpression of
SMC1A may lead to CRC development by inducing cell
growth and inhibiting apoptosis. However, determining
how SMC1A is relevant to the etiology of CRC requires
further investigation.
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